Abstract
PurposeAt our department, MR-guided stereotactic body radiation therapy (SBRT) using the 1.5T MR-linac system (Unity, Elekta AB, Stockholm, Sweden) has been initiated for patients with lymph node oligometastases. Superior soft tissue contrast and the possibility for online plan adaptation on the Unity may allow for hypofractionated treatment. The purpose of this study was to investigate the dosimetric feasibility and compare the plan quality of different hypofractionated schemes. Methods and materialsData was used from 12 patients with single lymph node oligometastases (10 pelvic, 2 para-aortic), which were all treated on the Unity with a prescribed dose of 5x7 Gy to 95% of the PTV. Hypofractionation was investigated for 3x10 Gy and 1x20 Gy schemes (all 60 Gy BED α/β = 10). The pre-treatment plans were evaluated based on dose criteria and plan quality. If all criteria were met, the number of online adapted plans which also met all dose criteria was investigated. For pre-treatment plans meeting the criteria for all three fractionation schemes, the plan quality after online adaptation was compared using the four parameters described in the NRG-BR001 phase 1 trial. ResultsPre-treatment plans met all clinical criteria for the three different fractionation schemes in 10, 9 and 6 cases. 50/50, 45/45 17/30 of the corresponding online adapted plans met all criteria, respectively. Violations were primarily caused by surrounding organs at risk overlapping or adjacent to the PTV. The 1x20 Gy treatment plans were, in general, of lesser quality than the 5x7 Gy and 3x10 Gy plans. ConclusionHypofractionated radiotherapy for lymph node oligometastases on the 1.5T MR-linac is feasible based on dose criteria and plan quality metrics. The location of the target relative to critical structures should be considered in choosing the most suitable fractionation scheme. Especially for single fraction treatment, meeting all dose criteria in the pre-treatment situation does not guarantee that this also applies during online treatment.
Highlights
At our department, MR-guided stereotactic body radiation therapy (SBRT) using the 1.5T MRlinac system (Unity, Elekta AB, Stockholm, Sweden) has been initiated for patients with lymph node oligometastases
Patient data was used from 12 patients with single lymph node oligometastases (10 pelvic, 2 para-aortic) with a median volume of 3.4 cm3 [range, 1.1–15.2 cm3], which were all treated on the 1.5T MR-linac (Unity, Elekta AB, Stockholm, Sweden) with a prescribed dose of 5x7 Gy to 95% of the planning target volume (PTV) (3 mm GTV-PTV margin)
In this study we showed that it is possible to deliver hypofractionated SBRT for lymph node oligometastases on the 1.5T MRlinac, meeting the clinical dose criteria for online adaptive treatment in the majority of cases
Summary
MR-guided stereotactic body radiation therapy (SBRT) using the 1.5T MRlinac system (Unity, Elekta AB, Stockholm, Sweden) has been initiated for patients with lymph node oligometastases. The purpose of this study was to investigate the dosimetric feasibility and compare the plan quality of different hypofractionated schemes. For pre-treatment plans meeting the criteria for all three fractionation schemes, the plan quality after online adaptation was compared using the four parameters described in the NRG-BR001 phase 1 trial. Results: Pre-treatment plans met all clinical criteria for the three different fractionation schemes in 10, 9 and 6 cases. Conclusion: Hypofractionated radiotherapy for lymph node oligometastases on the 1.5T MR-linac is feasible based on dose criteria and plan quality metrics. For single fraction treatment, meeting all dose criteria in the pre-treatment situation does not guarantee that this applies during online treatment. With single fraction treatment, delivered dose can be evaluated more accurately and advanced intra-fraction adaptation strategies can be more implemented [17]. Evidence indicates that SBRT with doses >10 Gy per fraction cause tumor vessel damage causing secondary and additional tumor cell death and may produce enhanced antitumor immunity [18,19]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
